JP7857914B2 - Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 - Google Patents

Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物

Info

Publication number
JP7857914B2
JP7857914B2 JP2023507923A JP2023507923A JP7857914B2 JP 7857914 B2 JP7857914 B2 JP 7857914B2 JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023507923 A JP2023507923 A JP 2023507923A JP 7857914 B2 JP7857914 B2 JP 7857914B2
Authority
JP
Japan
Prior art keywords
alkyl
cancer
halogen
mmol
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023507923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536504A5 (cg-RX-API-DMAC7.html
JP2023536504A (ja
Inventor
アッビネニ,チャンドラセカール
サマジダル,スサンタ
クイラ,ビラッシュ
ムカルジー,サブヘンドュ
ゴア,スーラジ タチャサヘブ
Original Assignee
オーリジーン オンコロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーリジーン オンコロジー リミテッド filed Critical オーリジーン オンコロジー リミテッド
Publication of JP2023536504A publication Critical patent/JP2023536504A/ja
Publication of JP2023536504A5 publication Critical patent/JP2023536504A5/ja
Priority to JP2026001041A priority Critical patent/JP2026082834A/ja
Application granted granted Critical
Publication of JP7857914B2 publication Critical patent/JP7857914B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023507923A 2020-08-04 2021-08-03 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物 Active JP7857914B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026001041A JP2026082834A (ja) 2020-08-04 2026-01-06 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041033326 2020-08-04
IN202041033326 2020-08-04
PCT/IB2021/057089 WO2022029617A1 (en) 2020-08-04 2021-08-03 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026001041A Division JP2026082834A (ja) 2020-08-04 2026-01-06 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物

Publications (3)

Publication Number Publication Date
JP2023536504A JP2023536504A (ja) 2023-08-25
JP2023536504A5 JP2023536504A5 (cg-RX-API-DMAC7.html) 2024-08-09
JP7857914B2 true JP7857914B2 (ja) 2026-05-13

Family

ID=80117730

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023507923A Active JP7857914B2 (ja) 2020-08-04 2021-08-03 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物
JP2026001041A Pending JP2026082834A (ja) 2020-08-04 2026-01-06 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026001041A Pending JP2026082834A (ja) 2020-08-04 2026-01-06 Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物

Country Status (11)

Country Link
US (2) US12570650B2 (cg-RX-API-DMAC7.html)
EP (1) EP4192835A4 (cg-RX-API-DMAC7.html)
JP (2) JP7857914B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230061349A (cg-RX-API-DMAC7.html)
CN (1) CN116529250A (cg-RX-API-DMAC7.html)
AU (1) AU2021320052A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002089A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188024A1 (cg-RX-API-DMAC7.html)
IL (1) IL300387A (cg-RX-API-DMAC7.html)
MX (1) MX2023001445A (cg-RX-API-DMAC7.html)
WO (1) WO2022029617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
AU2024348074A1 (en) 2023-09-27 2026-04-30 Haisco Pharmaceutical Group Co., Ltd. Pyrazole carboxylic acid derivative and use thereof in medicine
WO2025196686A1 (en) * 2024-03-20 2025-09-25 Aurigene Oncology Limited Fused bicyclic compounds as smarca2 and/or smarca4 degraders
CN119874808B (zh) * 2025-01-02 2026-04-17 四川大学 一种靶向smarca蛋白降解的化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195201A1 (en) 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2019207538A1 (en) 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders
JP2023510746A (ja) 2020-01-10 2023-03-15 アムジエン・インコーポレーテツド Smarca2-vhl分解剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2952188A1 (en) * 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
MA41598A (fr) * 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3319944A4 (en) * 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR20190140438A (ko) * 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195201A1 (en) 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2019207538A1 (en) 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders
JP2023510746A (ja) 2020-01-10 2023-03-15 アムジエン・インコーポレーテツド Smarca2-vhl分解剤

Also Published As

Publication number Publication date
JP2026082834A (ja) 2026-05-19
WO2022029617A1 (en) 2022-02-10
MX2023001445A (es) 2023-05-08
EP4192835A1 (en) 2023-06-14
CA3188024A1 (en) 2022-02-10
IL300387A (en) 2023-04-01
BR112023002089A2 (pt) 2023-02-28
US20240018134A1 (en) 2024-01-18
AU2021320052A1 (en) 2023-03-23
US12570650B2 (en) 2026-03-10
CN116529250A (zh) 2023-08-01
EP4192835A4 (en) 2024-08-21
JP2023536504A (ja) 2023-08-25
US20260184705A1 (en) 2026-07-02
KR20230061349A (ko) 2023-05-08

Similar Documents

Publication Publication Date Title
JP2026082834A (ja) Smarca2および/またはsmarca4分解剤としての6置換ピリダジン化合物
US12371426B2 (en) Pyridazine derivatives as SMARCA2/4 degraders
CN111285850B (zh) 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
EP2964223B1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN118005656A (zh) Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用
EP3686196B1 (en) Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor
AU2024360867A1 (en) Substituted tricyclic compounds as kras degraders
EP4212522A1 (en) Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof
CN112745298B (zh) 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途
AU2018269268B2 (en) Crystal of benzofuran derivative free base and preparation method
JP2024511342A (ja) フラン縮合環置換グルタルイミド系化合物
WO2024078581A1 (en) Selective bcl-xl protac compounds and uses thereof
WO2021041970A1 (en) Perk inhibiting imidazolopyrazine compounds
EP3617204A1 (en) Indoleamine 2,3-dioxygenase inhibitor and application
EA052684B1 (ru) 6​-замещенные пиридазиновые соединения в качестве деструкторов smarca2 и/или smarca4
RU2845145C1 (ru) Соединения для подавления рака с мутацией egfr и их фармацевтическое применение
JP2025506452A (ja) Smarca2及び/又はsmarca4分解剤としての3-置換ピリダジン化合物
KR20250170567A (ko) 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도
WO2026076223A1 (en) Therapeutic compounds and methods of use thereof
WO2025094065A1 (en) Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
EP4512807A1 (en) Bicycloamine carboxamide derivative
CN122059906A (zh) 用于抑制ptpn蛋白的化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260427

R150 Certificate of patent or registration of utility model

Ref document number: 7857914

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150